Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financi...(ine for the treatment of spinal cord inj...),Health

Date:5/14/2008

ine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that ma
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
2. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. Raises $5 Million
5. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
6. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
7. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
8. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
9. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
10. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
11. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement